Every material Form 8-K RenovoRx, Inc. has filed with the SEC since August 04, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
RenovoRx reported third-quarter 2026 revenue of $1.07 million, up from $266,000 a year earlier, and kept its full-year 2026 revenue guidance of $3.75 million to $4.25 million. The net loss widened to $3.6 million, or $0.08 per share, from $2.9 million, as selling, general and administrative expenses rose to $2.9 million from $1.7 million, so shareholders see faster sales growth alongside higher losses.
Q3 2026 revenue was $1.07 million versus $266,000 in Q3 2025; gross margin was about 82%.
Net loss was $3.6 million ($0.08 per share) versus $2.9 million ($0.08 per share) a year earlier.
Selling, general and administrative expenses were $2.9 million versus $1.7 million, which the company attributed to building commercial infrastructure.
Cash and cash equivalents were $10.4 million at September 30, 2026; the company says cash is sufficient into the second half of 2027.
RenovoRx said Nasdaq confirmed on August 20, 2026 that it has regained compliance with the Nasdaq minimum bid price requirement, and Nasdaq considers the matter closed. The closing bid price was at or above $1.00 per share for the ten consecutive business days from August 6 through August 19, 2026. The filing removes a listing deficiency that had been pending since December 31, 2025, but it reports no financial results or business changes.
Nasdaq notified RenovoRx on December 31, 2025 that its stock had closed below $1.00 for 30 consecutive business days.
Nasdaq confirmed on August 20, 2026 that the closing bid price was $1.00 or greater for ten consecutive business days, August 6 through August 19, 2026.
Nasdaq considers the minimum bid price matter closed; the filing reports no financial results or other business developments.
RenovoRx announced it will take part in a JonesTrading key opinion leader webinar on pancreatic cancer and its TAMP technology platform on August 13, 2026, at 1:30 p.m. ET, with CEO Shaun Bagai as a speaker. The filing contains no financial results, guidance, or new clinical data, so it is an informational event announcement for shareholders.
Webinar is scheduled for Thursday, August 13, 2026, at 1:30 p.m. ET, moderated by JonesTrading analyst Justin Walsh.
Speakers include CEO Shaun Bagai and two oncologists, Dae Won Kim, MD, of Moffitt Cancer Center and Ravi Shridhar, MD, PhD, of AdventHealth Cancer Institute.
The release cites RenovoCath sales of approximately $1.1 million in 2025 and a record $563,000 in the first quarter of 2026.
A replay will be available on the company's investor relations website.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every RenovoRx, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →